Evidence map›Paper›PMID 42319038›Full record

ArticleThe Journal of international medical research2026

Primary testicular neuroendocrine tumor: Diagnostic challenges and WHO 2022 classification insights.

Vida Garousi, Fattaneh Khalaj, Elham Mirzaian

Abstract readCase Reports
In one paragraph

Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Vida GarousiDepartment of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Iran.
Fattaneh KhalajLiver and Pancreatobiliary Diseases Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran.ORCID 0000-0003-0261-8202
Elham MirzaianDepartment of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Iran.ORCID 0000-0001-5408-3911

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary testicular neuroendocrine tumors are exceedingly rare, comprising less than 1% of testicular neoplasms. Their nonspecific presentation and overlap with other testicular tumors make diagnosis challenging. We report the case of a 21-year-old male with a painless left testicular mass. Imaging revealed a hypervascular lesion with calcifications, while serum markers (alpha-fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase) were normal. Radical orchiectomy demonstrated a 3-cm well-circumscribed tumor composed of monotonous cells with "salt-and-pepper" chromatin and low mitotic activity. Immunohistochemistry confirmed neuroendocrine differentiation (synaptophysin, chromogranin, INSM1 positive; Ki-67 < 1%). This profile established the diagnosis of a well-differentiated testicular neuroendocrine tumor, classified under the 2022 WHO framework as "prepubertal-type." Although indolent, these tumors require long-term follow-up due to the risk of late metastasis. Radical orchiectomy remains the treatment of choice. This case emphasizes the critical role of histopathology and immunoprofiling in diagnosis and contributes to refining the clinical understanding of this rare entity.

Indexed as

Neuroendocrine TumorsTesticular NeoplasmsBiomarkers, TumorHumansMaleOrchiectomyYoung AdultBiomarkers, TumorhistopathologyPrimary testicular neuroendocrine tumorscrotal masstesticular tumorWHO classification

Identifiers

PMID42319038
PMCPMC13305595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.